Progenies of NG2 glia: what do we learn from transgenic mouse models ?

被引：12
|
作者：
Guo, Qilin [1 ]
Scheller, Anja [1 ]
Huang, Wenhui [1 ]
机构：
[1] Univ Saarland, Ctr Integrat Physiol & Mol Med CIPMM, Mol Physiol, Homburg, Germany
来源：
NEURAL REGENERATION RESEARCH | 2021年 / 16卷 / 01期
基金：
欧盟地平线“2020”;
关键词：
SITE-SPECIFIC RECOMBINATION; OLIGODENDROCYTE LINEAGE; CORTICAL INTERNEURONS; WHITE-MATTER; CELLS; FATE; CNS; EXPRESSION; DIFFERENTIATION; PROTEOGLYCAN;
D O I：
10.4103/1673-5374.286950
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
In the mammalian central nervous system, nerve-glia antigen 2 (NG2) glia are considered the fourth glial population in addition to astrocytes, oligodendrocytes and microglia. The fate of NG2 glia in vivo has been carefully studied in several transgenic mouse models using the Cre/loxP strategy. There is a clear agreement that NG2 glia mainly serve as progenitors for oligodendrocytes and a subpopulation of astrocytes mainly in the ventral forebrain, whereas the existence of a neurogenic potential of NG2 glia is lack of adequate evidence. This mini review summarizes the findings from recent studies regarding the fate of NG2 glia during development. We will highlight the age-and-region-dependent heterogeneity of the NG2 glia differentiation potential. We will also discuss putative reasons for inconsistent findings in various transgenic mouse lines of previous studies.
引用
收藏
页码：43 / 48
页数：6
相关论文
共 50 条
  • [41] Astrocyte-like subpopulation of NG2 glia in the adult mouse cortex exhibits characteristics of neural progenitor cells
    Janeckova, Lucie
    Knotek, Tomas
    Kriska, Jan
    Hermanova, Zuzana
    Kirdajova, Denisa
    Kubovciak, Jan
    Berkova, Linda
    Tureckova, Jana
    Garcia, Sara Camacho
    Galuskova, Katerina
    Kolar, Michal
    Anderova, Miroslava
    Korinek, Vladimir
    GLIA, 2024, 72 (02) : 245 - 273
  • [42] Re-thinking osteoarthritis pathogenesis: what can we learn (and what do we need to unlearn) from mouse models about the mechanisms involved in disease development
    Raewyn C. Poulsen
    Lekha Jain
    Nicola Dalbeth
    Arthritis Research & Therapy, 25
  • [43] What do we learn from disciplined practice learning?
    Sheikh, K
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (06): : 447 - 447
  • [44] What do we learn from repeated population analyses?
    Duffull, Stephen B.
    Wright, Daniel F. B.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 79 (01) : 40 - 47
  • [45] What Do We Learn From Explant Analysis Programs?
    Chakfe, N.
    Heim, F.
    EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 2017, 54 (02) : 133 - 134
  • [46] Re-thinking osteoarthritis pathogenesis: what can we learn (and what do we need to unlearn) from mouse models about the mechanisms involved in disease development
    Poulsen, Raewyn C.
    Jain, Lekha
    Dalbeth, Nicola
    ARTHRITIS RESEARCH & THERAPY, 2023, 25 (01)
  • [47] What do we learn from schizophrenic subjects in remission?
    Koenig, M.
    Castillo, M. -C.
    Blanchet, A.
    Bouleau, J. -H.
    ANNALES MEDICO-PSYCHOLOGIQUES, 2011, 169 (03): : 179 - 182
  • [48] What do we learn from the genome of Legionella pneumophila?
    Cazalet, C
    Buchrieser, C
    M S-MEDECINE SCIENCES, 2005, 21 (05): : 455 - 457
  • [49] What do we learn from recent advances in neurophysiology?
    Hirsch, E.
    EPILEPSIA, 2006, 47 : 267 - 268
  • [50] DISPACT trial: what do we learn from equivalency?
    Hawkins, William G.
    Alseidi, Adnan
    LANCET, 2011, 377 (9776): : 1470 - 1471
12345